Tag: EMAG
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
Association seen in seniors with type 2 diabetes; greater associations seen for semaglutide and liraglutide
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
Higher protein intake may be protective against muscle loss, which is tied to less improvement in glucose homeostasis
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction
Semaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 Diabetes
Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
Strong outcomes seen in terms of weight loss, with lower doses of semaglutide used
